DeepMed Research

UCB BIOPHARMA SRL

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

Phase 3

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Dapirolizumab pegol

First Posted Date: 2021-07-26

Last Posted Date: 2025-05-16

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 760

Registration Number: NCT04976322

Locations: 🇺🇸
Sl0046 50273, Las Vegas, Nevada, United States
🇺🇸
Sl0046 50366, Canton, New York, United States
🇺🇸
Sl0046 50334, New York, New York, United States

and more 94 locations

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Phase 3

Active, not recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Drug: Bimekizumab

First Posted Date: 2021-05-25

Last Posted Date: 2025-05-11

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 658

Registration Number: NCT04901195

Locations: 🇨🇦
Hs0005 50174, London, Canada
🇨🇦
Hs0005 50190, Richmond Hill, Canada
🇨🇦
Hs0005 50192, Saskatoon, Canada

and more 142 locations

A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: brivaracetam

First Posted Date: 2021-05-12

Last Posted Date: 2023-03-13

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 12

Registration Number: NCT04882540

Locations: 🇨🇳
Ep0101 101, Shanghai, Shanghai, China

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Phase 2

Terminated

Conditions: Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Interventions: Drug: Placebo
Drug: Rozanolixizumab

First Posted Date: 2021-05-06

Last Posted Date: 2024-06-28

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 12

Registration Number: NCT04875975

Locations: 🇺🇸
Aie001 50342, Jacksonville, Florida, United States
🇺🇸
Aie001 50298, New York, New York, United States
🇺🇸
Aie001 50090, Winston-Salem, North Carolina, United States

and more 24 locations

A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease

Phase 1

Completed

Conditions: Healthy Study Participants
Parkinson's Disease

Interventions: Drug: UCB0022
Other: Placebo

First Posted Date: 2021-04-30

Last Posted Date: 2023-03-30

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 100

Registration Number: NCT04867642

Locations: 🇬🇧
Up0091 001, London, United Kingdom

A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

Phase 2

Active, not recruiting

Conditions: Alzheimer's Disease

Interventions: Other: Placebo
Biological: Bepranemab

First Posted Date: 2021-04-30

Last Posted Date: 2025-04-25

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 466

Registration Number: NCT04867616

Locations: 🇪🇸
Ah0003 40280, Sant Cugat Del Valles, Spain
🇪🇸
Ah0003 40049, Sevilla, Spain
🇪🇸
Ah0003 40453, Terrassa, Spain

and more 100 locations

A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: Alprazolam

First Posted Date: 2021-04-23

Last Posted Date: 2022-06-30

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 14

Registration Number: NCT04857307

Locations: 🇺🇸
Up0100 105, Memphis, Tennessee, United States
🇺🇸
Up0100 103, Honolulu, Hawaii, United States
🇺🇸
Up0100 106, Cincinnati, Ohio, United States

and more 5 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants

Phase 1

Completed

Conditions: Healthy Study Participants

Interventions: Drug: rozanolixizumab
Other: Placebo

First Posted Date: 2021-04-02

Last Posted Date: 2024-03-07

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 32

Registration Number: NCT04828343

Locations: 🇬🇧
Up0106 001, London, United Kingdom

A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma

Phase 1

Completed

Conditions: Participants With Mild Asthma
Healthy Study Participants

Interventions: Drug: Alprazolam
Other: Placebo

First Posted Date: 2021-03-17

Last Posted Date: 2023-11-28

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 78

Registration Number: NCT04802746

Locations: 🇺🇸
Up0099 102, Raleigh, North Carolina, United States
🇺🇸
Up0099 101, North Dartmouth, Massachusetts, United States

Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants

Phase 1

Completed

Conditions: Healthy Study Participants

Interventions: Drug: Alprazolam
Other: Placebo

First Posted Date: 2021-03-04

Last Posted Date: 2021-05-17

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 30

Registration Number: NCT04782388

Locations: 🇺🇸
Up0101 101, Anaheim, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy